#USA #New York #Lucid Diagnostics #EsoGuard #PAVmed

Lucid Diagnostics Q3 2025 Business and Financial Update

Lucid Diagnostics Inc. (Nasdaq: LUCD), a pioneering company in cancer prevention medical diagnostics, has recently released its business updates and financial results for the third quarter of 2025. The company aims to reshape cancer prevention for patients suffering from gastroesophageal reflux disease (GERD), who are at significant risk of esophageal neoplasia.

Highlights of Q3 2025

During this quarter, Lucid Diagnostics successfully processed 2,841 EsoGuard® tests, resulting in the recognition of $1.2 million in revenue. The company ended the quarter with an impressive cash balance exceeding $47 million, which positions it well for extended operational runway into 2026 and beyond. This financial strength bodes well as the company approaches crucial reimbursement milestones for its innovative diagnostics tools.

The highlight of the quarter was the unanimous expert consensus reached during a meeting of the Multi-Jurisdictional Contractor Advisory Committee (CAC) concerning Medicare Local Coverage Determination (LCD) for EsoGuard. This meeting marked a significant stride towards achieving Medicare coverage for EsoGuard, strongly backed by leading medical professionals.

The company's CEO, Dr. Lishan Aklog, expressed optimism following these developments, noting, "The overwhelmingly positive CAC meeting reinforces our confidence in entering the final stages of securing transformative coverage." Lucid's commitment to enhancing cancer prevention through early detection has never been more robust, as it scales its operations with ongoing support from a powerful market access team focused on engaging payors.

Strategic Initiatives and New Appointments

In addition to financial results, notable developments include the appointment of Danielle Scelfo as Senior Vice President for Market Access and Government Affairs. Scelfo's role will focus on strengthening Lucid's market access framework and tackling reimbursement activities targeting various payors.

Lucid is also participating in the Firefighter Esophageal Cancer Prevention Summit scheduled for November 19-20, aiming to foster advancements in early cancer detection tailored for the fire service community—an area particularly vulnerable to esophageal cancer due to specific lifestyle risk factors.

Financial Overview

For the quarter ending September 30, 2025, Lucid reported operating expenses of approximately $13 million, inclusive of $1.2 million in stock-based compensation. The GAAP net loss attributable to common stockholders was around $10.4 million, translating to a loss of $(0.10) per common share.

In light of the stock-based compensation and other adjustments, the company calculated its non-GAAP adjusted loss at approximately $10.3 million, maintaining a consistent operational focus despite significant investments in innovation and market access.

Lucid's cash reserves at the quarter's end were $47.3 million, a substantial increase from $22.4 million reported at the end of December 2024. This growth was further supported by a recent public offering yielding around $27 million in net proceeds, ensuring the company is well-prepared for ongoing research and development efforts.

Looking Ahead

Looking to the future, Lucid Diagnostics is excited about the trajectory it is on, particularly with the impending developments in reimbursement and Medicare coverage. The company's innovative approach to oncology, particularly aimed at preventing esophageal cancer through early detection, positions it as a key player in the healthcare landscape. As it continues to garner support from the medical community and increase its market visibility, Lucid remains committed to its mission of saving lives through early intervention and meticulous cancer prevention strategies.

For more information about Lucid Diagnostics and its revolutionary efforts in cancer detection, please visit luciddx.com.